Welcome to our dedicated page for Nanalysis Sci news (Ticker: NSCIF), a resource for investors and traders seeking the latest updates and insights on Nanalysis Sci stock.
Nanalysis Scientific Corp. (OTCQX: NSCIF; TSXV: NSCI; FRA: 1N1) is an analytical laboratory instrument manufacturer focused on portable Nuclear Magnetic Resonance (NMR) spectrometers and related magnetic resonance technology, alongside a Security Services division centered on airport security equipment maintenance. The news flow around Nanalysis reflects both its technology roadmap and its operational and financial performance.
On this page, readers can follow company announcements on quarterly and year-to-date financial results, where Nanalysis reports trends in product sales, security services revenue, gross margins, Adjusted EBITDA, and normalized net loss. These releases often discuss the impact of macroeconomic conditions, such as tariff and trade uncertainty, on capital equipment demand, as well as the effects of cost-reduction and continuous improvement programs in manufacturing and services.
News items also cover business development and technology milestones, including OEM and licensing agreements for MRI consoles, collaborations with software providers like Wiley’s KnowItAll for NMR data analysis, and regulatory developments such as the acceptance of a benchtop NMR assay by the United States Pharmacopeia and the European Pharmacopoeia. Updates on the company’s Security Services segment, including operational changes in its airport security maintenance business and the execution of its long-term contract with the Canadian Air Transport Security Authority (CATSA), are another recurring theme.
Investors and observers can also see announcements related to financing activities, such as private placements of units and promissory notes, amendments to loan facilities, and management changes. For anyone tracking NSCIF, this news feed provides a consolidated view of how Nanalysis is managing its benchtop NMR and MRI technology platforms, its security services operations, and its capital structure over time.
Nanalysis (OTCQX: NSCIF, TSXV: NSCI) closed the second and final tranche of its $3.4 million non‑brokered private placement on Jan 26, 2026. The Second Tranche issued 6,145,300 units at $0.15 per unit for gross proceeds of $921,795, bringing the Offering total to 22,671,583 units. Each unit includes one share and one‑half warrant; each whole warrant allows purchase of one share at $0.20 until two years from closing, subject to acceleration if the share price trades at $0.30 for 10 consecutive trading days. The company paid $2,000 in finder’s fees to Leede Financial and securities remain subject to a statutory hold period of four months plus one day. TSX Venture final acceptance is pending.
Nanalysis (OTCQX: NSCIF) closed the first tranche of a non‑brokered private placement on Dec 23, 2025, issuing 16,526,283 Units at $0.15 each for gross proceeds of about $2.5M. Each Unit includes one share and one‑half warrant; each full warrant is exercisable at $0.20 until two years from closing with acceleration if the share price trades at $0.30 for 10 consecutive days. The company upsized the Offering to allow issuance of up to an additional 23,333,333 Units for up to $3.5M, subject to TSX Venture Exchange approval. Net proceeds are earmarked for debt reduction and magnet inventory purchases; securities issued carry a statutory four‑month plus one‑day hold.
Nanalysis (OTCQX: NSCIF) announced a non-brokered private placement of up to 16,666,667 Units at $0.15 per Unit to raise up to $2,500,000 in gross proceeds. Each Unit comprises one common share and one-half of one warrant; the 8,333,333 whole Warrants will be exercisable at $0.20 per share until two years from closing and include an acceleration clause if the share price trades at $0.30 for 10 consecutive trading days. Net proceeds are designated for debt reduction. Closing is subject to TSX Venture Exchange acceptance, may occur in tranches, and an initial close is anticipated on or about December 15, 2025. Securities will carry a statutory hold period of four months and one day.
Nanalysis Scientific Corp. (OTCQX: NSCIF) reported Q3 2025 consolidated revenue of $9,285K, down 12% year-over-year, and nine-month revenue of $29,455K, down 11% year-over-year. Product sales declined sharply: $2,719K in Q3 (-36% YoY) and $9,308K YTD (-33% YoY). Security services revenue grew: Q3 $5,943K (+10% YoY) and YTD $16,583K (+8% YoY). Q3 product gross margin fell to 44% from 52%, while nine-month product margin improved to 58% from 50%. Adjusted EBITDA was ($2K) for Q3 and ($284K) YTD. Net loss improved to ($1,500K) in Q3 and ($4,929K) YTD. The company executed a five-year OEM and licensing agreement with IMRIS, resolved magnet supply constraints, and is restructuring its sales organization to refocus on benchtop NMR sales.
Nanalysis (OTCQX: NSCIF) announced a management change: Randall McRae will resign as Chief Financial Officer effective December 5, 2025 and will remain available to the company in an advisory capacity after his departure.
Heather Kury, Corporate Controller, will be appointed Interim Chief Financial Officer while the board searches for a permanent successor. Ms. Kury is a CPA, CA with over 20 years' experience, holds a Bachelor of Arts (Accounting and History) from the University of Winnipeg, and is a member of the Institute of Chartered Professional Accountants of Alberta.
Nanalysis (OTCQX: NSCIF) announced native file support for its portable NMR instruments in Wiley KnowItAll 2026, enabling direct import of raw low-field NMR files into KnowItAll and two-way workflow integration.
The update lets KnowItAll users run low-field NMR analysis inside a multi‑technique platform and lets Nanalysis users access KnowItAll’s processing, prediction, searching and Wiley’s spectral libraries, which contain over 1.28 million 1D spectra across 1H, 13C and multiple X‑NMR nuclei. Subscription required for some libraries.
Nanalysis Scientific Corp. (OTCQX: NSCIF) has secured a significant five-year OEM supplier and technology licensing agreement with IMRIS Imaging, Inc., a leader in intraoperative MRI. The non-exclusive agreement includes an upfront payment and builds upon a previous 12-month contract.
The partnership leverages Nanalysis's core electronics and software technology platform, which is utilized across their benchtop NMR, high-field NMR, and MRI products. IMRIS has validated Nanalysis's MRI console during system prototyping, positioning the company as a critical component supplier for IMRIS's integrated operating suites.
Nanalysis Scientific Corp. (OTCQX: NSCIF) reported challenging Q2 2025 results marked by a 17% decline in total revenue to $9.6 million. Product sales dropped significantly by 46% to $2.9 million, while security services revenue increased by 7% to $5.6 million.
Despite revenue challenges, the company achieved notable improvements in product sales gross margins, increasing to 61% from 50% year-over-year. The company reported an Adjusted EBITDA loss of $462,000 compared to a profit of $759,000 in Q2 2024, and a net loss of $2.1 million.
Key developments include closing a $2 million promissory note financing, implementing efficiency measures in security services, and securing loan amendments to reduce principal payments through April 2026.
Nanalysis Scientific Corp. (OTCQX: NSCIF), a leader in portable NMR instruments and imaging technology, has scheduled its Q2 2025 earnings conference call for August 28th, 2025 at 5:00 PM ET. CEO Sean Krakiwsky and CFO Randall McRae will host the call to discuss results for the quarter ended June 30, 2025.
Investors can participate by dialing 1-437-900-0527 or 1-888-510-2154 from abroad, or access the webcast through the company's investor relations website. A separate European Q&A session will be held on August 29th at 8:30 AM ET. The webcast will be archived for 90 days, and a playback will be available for seven days.
Nanalysis Scientific Corp. (OTCQX: NSCIF) has achieved a significant milestone with the first regulatory certified assay for benchtop Nuclear Magnetic Resonance (NMR) being accepted by the United States Pharmacopeia (USP) and European Pharmacopeia. The certified method is for Molar Substitution Determination in Hydroxypropyl Betadex, an important excipient used in various pharmaceutical products.
This breakthrough enables the use of 60 MHz benchtop NMR for pharmaceutical quality control, marking a shift from traditional expensive and complex superconducting high-field NMR technology. The company is actively developing additional formal methods for ASTM, AOAC, and ISO standards, positioning benchtop NMR for widespread industrial adoption.
FAQ
What is the current stock price of Nanalysis Sci (NSCIF)?
What is the market cap of Nanalysis Sci (NSCIF)?
